|
|
Article: Neurocrine Reports Positive Results for Indiplon in Adults With Transient Insomnia; Indiplon Modified Release Formulation Demonstrates Statistically Significant Improvement in Sleep Initiation.
- Article from:
- PR Newswire
- Article date:
- March 1, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences, Inc. today announced positive results from its Phase III trial with the modified release formulation of indiplon, achieving highly statistically significant results in adults with transient insomnia. The study was a randomized, double-blind, placebo-controlled, parallel-group, multi-center sleep laboratory Phase III clinical trial. The primary objective of the study was to assess the efficacy of two dose levels of indiplon modified release (20 mg and 30 mg) relative to placebo on sleep initiation in 325 healthy adult subjects. The primary endpoint for the study was Latency to Persistent Sleep (LPS), or time to sleep onset, as measured objectively ...